Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HOXC8 siRNA refers to small interfering RNA molecules specifically designed to target and silence the expression of the Homeobox C8 (HOXC8) gene. HOXC8 is a transcription factor implicated in various biological processes, including cellular development, differentiation, and tumorigenesis. The mechanism of action involves RNA interference (RNAi), where the siRNA binds to complementary messenger RNA (mRNA) sequences of the HOXC8 gene, leading to the degradation of the mRNA and subsequent inhibition of HOXC8 protein synthesis. This gene silencing approach is utilized in research to investigate the functional roles of HOXC8 in diseases such as cervical cancer, breast cancer, and prostate cancer, where its aberrant expression is often observed. HOXC8 siRNA is primarily used as a research tool to study gene function and explore potential therapeutic strategies by downregulating HOXC8 expression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HOXC8 siRNA.